MUNICH – German biotech company AMSilk has raised an additional €25 million in an extended Series C financing round to scale the global production of its bio-fabricated silk proteins.
This latest round comes after it raised €29 million in Series C funds back in 2021 and boosts its recent funding levels to €54 million.
The firm reprograms microorganisms to enable them to make silk proteins into usable forms such as powders, hydrogels, fibres, and coatings for various market segments including textiles, medical use and other consumer goods.
